2 例胰岛素瘤相关低血糖的患者给予卡比多巴预处理后的动态 18F-FDOPA PET 检查结果
Dynamic 18F-FDOPA PET Findings After Carbidopa Premedication in 2 Adult Patients With Insulinoma-Related Hyperinsulinemic Hypoglycemia.
机构信息
From the *Department of Biophysics and Nuclear Medicine, University Hospitals of Strasbourg; †ICube, UMR 7357 University of Strasbourg/CNRS and FMTS, Faculty of Medicine; Departments of ‡Diabetology, §Internal Medicine, Diabetes and Metabolic Disorders, and ∥Visceral Surgery and Transplantation, University Hospitals of Strasbourg, Strasbourg; and ¶Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France.
出版信息
Clin Nucl Med. 2015 Aug;40(8):682-4. doi: 10.1097/RLU.0000000000000686.
(18)F-fluorodihydroxyphenylalanine (FDOPA) PET seems to be of limited value to localize pancreatic insulin-secreting tumors in adult with hyperinsulinemic hypoglycemia. Carbidopa is an efficient inhibitor of the peripheral aromatic amino acid decarboxylase, significantly reducing the physiological pancreatic FDOPA uptake. Nevertheless, carbidopa effect on FDOPA uptake in insulinomas is not fully elucidated. No final consensus has been reached about the usefulness of carbidopa in patients with insulinoma-related hyperinsulinemic hypoglycemia. Moreover, the ideal timing for PET/CT acquisitions is a matter of discussion. We report the results of dynamic FDOPA PET performed after carbidopa premedication in 2 adult patients with insulinoma.
(18)F-氟代二羟苯丙氨酸（FDOPA）PET 似乎对定位成人高胰岛素血症低血糖相关的胰腺胰岛素分泌肿瘤没有价值。卡比多巴是外周芳香族氨基酸脱羧酶的有效抑制剂，可显著减少胰腺 FDOPA 的生理性摄取。然而，卡比多巴对胰岛素瘤中 FDOPA 摄取的影响尚未完全阐明。关于卡比多巴在胰岛素瘤相关高胰岛素血症低血糖患者中的作用，尚未达成最终共识。此外，PET/CT 采集的理想时间也是一个讨论的问题。我们报告了在 2 例胰岛素瘤患者中进行卡比多巴预处理后的 FDOPA PET 动态研究结果。
Zotero 插件